BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 30614545)

  • 1. PTEN abnormalities predict poor outcome in children with T-cell acute lymphoblastic leukemia treated according to ALL IC-BFM protocols.
    Szarzyńska-Zawadzka B; Kunz JB; Sędek Ł; Kosmalska M; Zdon K; Biecek P; Bandapalli OR; Kraszewska-Hamilton M; Jaksik R; Drobna M; Kowalczyk JR; Szczepański T; Van Vlierberghe P; Kulozik AE; Witt M; Dawidowska M
    Am J Hematol; 2019 Apr; 94(4):E93-E96. PubMed ID: 30614545
    [No Abstract]   [Full Text] [Related]  

  • 2. Prediction of outcome by early bone marrow response in childhood acute lymphoblastic leukemia treated in the ALL-BFM 95 trial: differential effects in precursor B-cell and T-cell leukemia.
    Lauten M; Möricke A; Beier R; Zimmermann M; Stanulla M; Meissner B; Odenwald E; Attarbaschi A; Niemeyer C; Niggli F; Riehm H; Schrappe M
    Haematologica; 2012 Jul; 97(7):1048-56. PubMed ID: 22271901
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Augmented Berlin-Frankfurt-Munster therapy abrogates the adverse prognostic significance of slow early response to induction chemotherapy for children and adolescents with acute lymphoblastic leukemia and unfavorable presenting features: a report from the Children's Cancer Group.
    Nachman J; Sather HN; Gaynon PS; Lukens JN; Wolff L; Trigg ME
    J Clin Oncol; 1997 Jun; 15(6):2222-30. PubMed ID: 9196134
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thromboembolic events in children with acute lymphoblastic leukemia (BFM protocols): prednisone versus dexamethasone administration.
    Nowak-Göttl U; Ahlke E; Fleischhack G; Schwabe D; Schobess R; Schumann C; Junker R
    Blood; 2003 Apr; 101(7):2529-33. PubMed ID: 12517808
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug Rash, Eosinophilia, Systemic Symptoms (DRESS) in a Child With Acute Lymphoblastic Leukemia.
    Thakkar D; Singh Y; Yadav SP
    J Pediatr Hematol Oncol; 2018 May; 40(4):e266-e267. PubMed ID: 29189510
    [No Abstract]   [Full Text] [Related]  

  • 6. Lineage classification of childhood acute lymphoblastic leukemia according to the EGIL recommendations: results of the ALL-BFM 2000 trial.
    Ratei R; Schabath R; Karawajew L; Zimmermann M; Möricke A; Schrappe M; Ludwig WD
    Klin Padiatr; 2013 May; 225 Suppl 1():S34-9. PubMed ID: 23700065
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Second neoplasm in children treated in EORTC 58881 trial for acute lymphoblastic malignancies: low incidence of CNS tumours.
    Renard M; Suciu S; Bertrand Y; Uyttebroeck A; Ferster A; van der Werff Ten Bosch J; Mazingue F; Plouvier E; Robert A; Boutard P; Millot F; Munzer M; Mechinaud F; Lescoeur B; Baila L; Vandecruys E; Benoit Y; Philippet P;
    Pediatr Blood Cancer; 2011 Jul; 57(1):119-25. PubMed ID: 21412967
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-alcoholic steatohepatitis induced by induction chemotherapy for pediatric acute lymphoblastic leukemia.
    Yamamoto M; Hori T; Igarashi K; Iesato K; Saito M; Miyanishi K; Kikuchi N; Fujita H; Tsutsumi H
    Int J Hematol; 2018 Apr; 107(4):390-391. PubMed ID: 29181701
    [No Abstract]   [Full Text] [Related]  

  • 9. No advantage of a rotational continuation phase in acute lymphoblastic leukemia in childhood treated with a BFM back-bone therapy.
    Felice MS; Rossi JG; Gallego MS; Alfaro EM; Zubizarreta PA; Fraquelli LE; Alonso CN; Guitter MR; Scopinaro MJ
    Pediatr Blood Cancer; 2011 Jul; 57(1):47-55. PubMed ID: 21394895
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-risk childhood acute lymphoblastic leukemia in first remission treated with novel intensive chemotherapy and allogeneic transplantation.
    Marshall GM; Dalla Pozza L; Sutton R; Ng A; de Groot-Kruseman HA; van der Velden VH; Venn NC; van den Berg H; de Bont ES; Maarten Egeler R; Hoogerbrugge PM; Kaspers GJ; Bierings MB; van der Schoot E; van Dongen J; Law T; Cross S; Mueller H; de Haas V; Haber M; Révész T; Alvaro F; Suppiah R; Norris MD; Pieters R
    Leukemia; 2013 Jul; 27(7):1497-503. PubMed ID: 23407458
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term results of AIEOP-8805 protocol for acute B-cell lymphoblastic leukemia of childhood.
    Pillon M; Aricò M; Basso G; Locatelli F; Citterio M; Micalizzi C; Testi AM; Barisone E; Nardi M; Lombardi A; Rondelli R; Rosolen A;
    Pediatr Blood Cancer; 2011 Apr; 56(4):544-50. PubMed ID: 21298738
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The presence of mutated and deleted PTEN is associated with an increased risk of relapse in childhood T cell acute lymphoblastic leukaemia treated with AIEOP-BFM ALL protocols.
    Paganin M; Grillo MF; Silvestri D; Scapinello G; Buldini B; Cazzaniga G; Biondi A; Valsecchi MG; Conter V; Te Kronnie G; Basso G
    Br J Haematol; 2018 Sep; 182(5):705-711. PubMed ID: 29938780
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The prospects for children with acute lymphoblastic leukemia of being cured has increased in the Czech Republic in the 21st century to 90% - outcome of the ALL-IC BFM 2002 trial].
    Zdráhalová K; Štěrba J; Domanský J; Blažek B; Ptoszková H; Mihál V; Novák Z; Hak J; Procházková D; Černá Z; Timr P; Jabali Y; Sedláček P; Smíšek P; Zemanová Z; Jarošová M; Houdková A; Mejstříková E; Hrušák O; Zuna J; Janotová I; Trka J; Starý J
    Cas Lek Cesk; 2015; 154(2):79-89. PubMed ID: 25994910
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neurophysiological findings in long-term survivors of acute lymphoblastic leukaemia in childhood treated with the BFM protocol 81 SR-A/B.
    Ueberall MA; Skirl G; Strassburg HM; Wenzel D; Hertzberg H; Langer T; Meier W; Berger-Jones K; Huk WJ; Korinthenberg R; Beck JD
    Eur J Pediatr; 1997 Sep; 156(9):727-33. PubMed ID: 9296540
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human granulocyte colony-stimulating factor in children with high-risk acute lymphoblastic leukemia: a Children's Cancer Group Study.
    Heath JA; Steinherz PG; Altman A; Sather H; Jhanwar S; Halpern S; Pieters R; Shah N; Steinherz L; Tannous R; Terry W; Trigg ME;
    J Clin Oncol; 2003 Apr; 21(8):1612-7. PubMed ID: 12697887
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prediction of outcome by early response in childhood acute lymphoblastic leukemia.
    Möricke A; Lauten M; Beier R; Odenwald E; Stanulla M; Zimmermann M; Attarbaschi A; Niggli F; Schrappe M
    Klin Padiatr; 2013 May; 225 Suppl 1():S50-6. PubMed ID: 23700057
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prothrombotic risk factors in children with acute lymphoblastic leukemia treated with delayed E. coli asparaginase (COALL-92 and 97 protocols).
    Mauz-Körholz C; Junker R; Göbel U; Nowak-Göttl U
    Thromb Haemost; 2000 Jun; 83(6):840-3. PubMed ID: 10896235
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The long-term results of childhood acute lymphoblastic leukemia at two centers from Turkey: 15 years of experience with the ALL-BFM 95 protocol.
    Güneş AM; Oren H; Baytan B; Bengoa SY; Evim MS; Gözmen S; Tüfekçi O; Karapınar TH; Irken G
    Ann Hematol; 2014 Oct; 93(10):1677-84. PubMed ID: 24863691
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improved treatment outcome in Chinese children and adolescents with Burkitt's lymphoma and large cell lymphoma by using the modified B-non-Hodgkin's lymphoma-Berlin-Frankfurt-Münster-90 protocol.
    Sun XF; Zhen ZJ; Lui DG; Xia Y; He YJ; Wang ZH; Lin JY; Guan ZZ
    Eur J Haematol; 2006 Nov; 77(5):365-71. PubMed ID: 16879606
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Results of treatment of children with acute lymphoblastic leukemia with a modified BFM protocol].
    Janić D; Dokmanović L; Jovanović N; Skorić D; Lazić J
    Srp Arh Celok Lek; 2004 Oct; 132 Suppl 1():17-22. PubMed ID: 15615459
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.